Livestream: Optimizing Ulcerative Colitis Management: Navigating Challenges and Enhancing Outcomes in Managed Care

Ulcerative colitis (UC) affects around three million people in the United States. Delays in treatment coverage approval, costs of managing the disease, and uncertainties around new treatment options significantly impact how well patients react to treatment, and short- and long-term outcomes. Waiting too long to start treatment not only raises the chances of serious complications, but also leads to more doctor visits and higher costs. Managed care professionals find themselves in the middle of this friction, and prompt access to treatment relies on understanding of the latest data for proper positioning of therapies on formulary. As new treatments emerge, it is essential to determine which treatments are preferred based on safety and efficacy data that prove clinical significance and drive decisions for patient coverage.

In this CME Outfitters hybrid educational symposium led by a multi-disciplinary panel of UC experts, clinicians will learn about the changes happening in the UC treatment landscape, which treatments may offer patients with UC a higher quality of life, and which UC treatments have significant long-term benefit, thus optimizing access to the best treatments available to patients in different stages of disease.

At the conclusion of this activity, learners will be able to better:

• Identify how delays in diagnosis and treatment initiation negatively impact patient outcomes in UC
• Evaluate the economic consequences of suboptimal treatment in patients with moderate-to-severe UC
• Incorporate the latest data and guidelines for the treatment of UC into population health decisions

Managed care professionals including physicians, physician associates (PAs), and pharmacists, payers, pharmacy benefit managers, and clinicians within IDSs

Dr. Naik reports the following financial relationships:

Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Eli Lilly & Company; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: AbbVie Inc.; Bristol Myers Squibb Company; Eli Lilly & Company; and Takeda Pharmaceuticals U.S.A., Inc.

Dr. Benson reports no financial relationships to disclose.

The following individuals have no financial relationships to disclose: 

Rebecca Vargas-Jackson, MD  (Peer Reviewer)
Joshua Caballero, PharmD, BCPP, FCCP  (Peer reviewer)
Thomas Mitchell, MSW (Planning Committee)
John Jones, PharmD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Call us at 877.CME.PROS (877.263.7767).

MMS-145-101524-11